- Strengthens the Company’s intellectual property portfolio for lead in vivo program PBGENE-HBV with U.S. patent protection into 2042- - Phase 1 ELIMINATE-B trial progressing through clinical investigation with dosing of Cohort 3 initiated in Third Quarter of 2025- DURHAM, N.C.